- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Expert Calls for Improved Home Care Options for Those With Debilitating Diseases
Karen Davis, director of Roger C. Lipitz Center for Integrated Health Care at Johns Hopkins University, says increasing resources available for home treatments and services and support for family caregivers of the elderly and those with debilitating diseases might work to reduce reliance on costly nursing homes for those afflicted.
Lawmakers should consider widening the mandate of the federal Center for Medicare and Medicaid Innovation, known as CMMI, to allow more work on programs that could keep people with debilitating illnesses in their homes longer, a researcher said during a recent briefing on the program's future.
"At some point, we may need to look at whether the CMMI authorizing legislation needs to be broadened a bit," said Karen Davis, director of Roger C. Lipitz Center for Integrated Health Care at Johns Hopkins University. However, that approach would be met with resistance from congressional Republicans when funding for the Centers for Medicare and Medicaid Services' Innovation Center comes up for renewal after fiscal 2019.
Read the complete article on The Commonwealth Fund website: http://bit.ly/1B7Cdi0
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More
